A nurse is caring for a patient who has been taking lorazepam (Ativan) 2 mg twice daily for anxiety for the past 6 months. The patient reports wanting to discontinue the medication. What is the most important nursing action?

Benzodiazepines like lorazepam require gradual tapering under medical supervision to prevent dangerous withdrawal symptoms such as seizures. Other options risk abrupt withdrawal or inappropriate substitution.

Understanding the Clinical Scenario
The patient has been on a consistent dose of lorazepam (Ativan), a benzodiazepine receptor agonist (BZRA), for 6 months. This duration of use is significant because it extends well beyond the short-term treatment window, establishing a high probability of physical dependence. The patient's desire to stop the medication is a critical moment where nursing intervention must prioritize safety by preventing a potentially severe withdrawal syndrome.

Why Immediate Discontinuation or Self-Tapering is Dangerous
Advising the patient to stop immediately (Option 1) or to reduce the dose by half every few days (Option 3) contradicts the pharmacological principles of safe BZRA deprescribing. Abrupt cessation or rapid, linear reductions are high-risk strategies. After 6 months of use, the patient’s neurophysiology has adapted to the presence of the drug. A sudden drop in dosage can trigger a severe and protracted withdrawal syndrome ^[4]. Symptoms are not merely a return of anxiety but can include life-threatening complications such as seizures, psychosis, and severe autonomic instability. A meta-analysis of deprescribing interventions confirms that structured, gradual strategies are necessary to mitigate these harms, and that simply advising a patient to reduce without a tailored plan is often unsuccessful and unsafe ^[1].

The Pharmacological Basis for Gradual, Hyperbolic Tapering
The most current evidence-based guidance moves away from linear dose reductions (e.g., cutting by 1 mg at a time) and instead recommends a gradual, proportionate (hyperbolic) tapering schedule ^[4]. This means reducing the dose by a percentage of the most recent dose (e.g., 5-10% every 1-4 weeks), not the original dose. This approach accounts for the hyperbolic relationship between BZRA receptor occupancy and drug dose, meaning that at lower doses, even small absolute reductions can lead to a massive drop in receptor occupancy, triggering intense withdrawal. A modified Delphi consensus from a multi-disciplinary expert panel explicitly recommends this individualized, flexible approach to minimize withdrawal symptoms and optimize deprescribing success, highlighting that standard, rigid protocols often fail .

The Nurse's Role in Collaborative Management
The most important nursing action is to collaborate with the healthcare provider (Option 4). As a nurse, you are not authorized to prescribe a tapering schedule, but you are responsible for recognizing the risk, advocating for the patient, and facilitating a safe plan. A systematic review focused on older adults confirms that structured deprescribing strategies, which are inherently collaborative and multidisciplinary, are the standard of care to safely reduce chronic BZRA use . Recommending an over-the-counter substitute (Option 2) is inappropriate and potentially dangerous, as it does not address the underlying BZRA dependence and could lead to additive sedation or other adverse effects. The nurse’s role is to educate the patient on why a gradual, provider-supervised taper is medically necessary, to monitor for withdrawal symptoms using a validated tool, and to provide non-pharmacological support throughout the process. The evidence is clear that a successful deprescribing plan is one that is individualized, gradual, and managed by a healthcare team, not a self-directed or abrupt cessation attempt [2,4].